Lifecore Biomedical Inc Quick Ratio (LFCR) starting from the first quarter 2026 to first quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Lifecore Biomedical Inc   (NASDAQ: LFCR)

Lifecore Biomedical Inc 's Quick Ratio

LFCR's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Lifecore Biomedical Inc 's Cash & cash equivalent grew by 10.28 % in the Q1 2026 sequentially, while Current Liabilities decreased, this led to improvement in Lifecore Biomedical Inc 's Quick Ratio to 1.01, above Lifecore Biomedical Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 333 other companies have achieved higher Quick Ratio than Lifecore Biomedical Inc in first quarter 2026. While Quick Ratio total ranking has improved so far during the Q1 2026 to 1625, from total ranking in the first quarter 2025 at 1857.

Explain Quick Ratio?
How much Cash & cash equivalents LFCR´s has?
What are LFCR´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LFCR Quick Ratio (Mar 31 2026)
Q1		 (Sep 30 2025)
Q1		 (May 25 2025)
Q4		 (Feb 23 2025)
Q3		 (Nov 24 2024)
Q2
Y / Y Current Liabilities Change -47.27 % -26.07 % -45.99 % -26.24 % -1.06 %
Y / Y Cash & cash equivalent Change 145.75 % 241.59 % -2.33 % 76.28 % -55.68 %
Quick Ratio MRQ 1.01 0.63 0.27 0.2 0.22
LFCR's Total Ranking # 1625 # 1857 # 1641 # 2860 #
Seq. Current Liabilities Change -31.58 % -0.73 % 11.15 % -30.16 % -4.07 %
Seq. Cash & cash equivalent Change 10.28 % 128.14 % 52.58 % -35.98 % 53.3 %



Quick Ratio first quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 334
Healthcare Sector # 588
Overall Market # 1625


Quick Ratio Statistics
High Average Low
1.05 0.18 0
(Feb 26 2012)   (May 31 2020)




Financial Statements
Lifecore Biomedical Inc 's Current Liabilities $ 20 Millions Visit LFCR's Balance sheet
Lifecore Biomedical Inc 's Cash & cash equivalent $ 21 Millions Visit LFCR's Balance sheet
Source of LFCR's Sales Visit LFCR's Sales by Geography


Cumulative Lifecore Biomedical Inc 's Quick Ratio

LFCR's Quick Ratio for the trailling 12 Months

LFCR Quick Ratio

 (Mar 31 2026)
12 Months		 (Sep 30 2025)
12 Months		 (May 25 2025)
12 Months		 (Feb 23 2025)
12 Months		 (Nov 24 2024)
12 Months
Y / Y Current Liabilities TTM Growth -37.37 % -26.86 % -18.32 % 7.71 % 13.46 %
Y / Y Cash & cash equivalent TTM Growth 109.01 % 13.43 % -29.55 % -44.16 % -48.73 %
Quick Ratio TTM 0.49 0.32 0.2 0.17 0.15
Total Ranking TTM # 3164 # 3382 # 1977 # 1268 #
Seq. Current Liabilities TTM Growth -14.57 % -7.73 % -15.82 % -5.61 % -0.24 %
Seq. Cash & cash equivalent TTM Growth 30.08 % 48.21 % -0.71 % 9.19 % -29.41 %

Quick ratio ranking by company, industry and sector >> Back to LFCR Financial Strength Comparisons >> Go to Compare LFCR Quick Ratio to its Competitors

On the trailing twelve months basis LFCR Cash & cash equivalent more than doubled by 145.75 % in Q1 2026 year on year, while Current Liabilities plummeted to $20 millions, this led to increase in in Lifecore Biomedical Inc 's Quick Ratio to 0.49, above LFCR average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 406 other companies have achieved higher Quick Ratio than Lifecore Biomedical Inc . While Quick Ratio overall ranking has improved so far to 3164, from total ranking during the twelve months ending first quarter 2025 at 3382.

Explain Quick Ratio?
How much Cash & cash equivalents LFCR´s has?
What are LFCR´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 407
Healthcare Sector # 834
Within the Market # 3164


trailing twelve months Quick Ratio Statistics
High Average Low
0.48 0.16 0.01
(Mar 31 2026)   (May 29 2022)




Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2026 MRQ Cash & cash equivalentMar 31 2026 MRQ Current Liabilities
Acadia Pharmaceuticals Inc   2.79 $ 851.458  Millions$ 305.524  Millions
Rafael Holdings Inc  2.79 $ 30.497  Millions$ 10.950  Millions
Oramed Pharmaceuticals Inc  2.77 $ 29.264  Millions$ 10.563  Millions
Tg Therapeutics Inc   2.75 $ 514.430  Millions$ 187.108  Millions
Verastem Inc   2.72 $ 181.678  Millions$ 66.845  Millions
Annovis Bio Inc   2.70 $ 14.219  Millions$ 5.276  Millions
Ionis Pharmaceuticals Inc   2.68 $ 1,919.113  Millions$ 716.591  Millions
Precigen Inc   2.67 $ 56.246  Millions$ 21.104  Millions
Ernexa Therapeutics Inc   2.65 $ 9.177  Millions$ 3.457  Millions
Lixte Biotechnology Holdings Inc   2.65 $ 3.251  Millions$ 1.225  Millions
Revium Rx.  2.65 $ 2.139  Millions$ 0.807  Millions
Beone Medicines Ltd   2.65 $ 4,791.676  Millions$ 1,811.510  Millions
Metavia Inc   2.64 $ 13.731  Millions$ 5.192  Millions
Quoin Pharmaceuticals Ltd   2.63 $ 14.043  Millions$ 5.346  Millions
Xoma Royalty Corporation  2.59 $ 85.600  Millions$ 33.077  Millions
Gyre Therapeutics Inc   2.52 $ 49.808  Millions$ 19.788  Millions
Cocrystal Pharma Inc   2.48 $ 4.685  Millions$ 1.886  Millions
Pyxis Oncology Inc   2.48 $ 41.018  Millions$ 16.532  Millions
Fortress Biotech Inc   2.47 $ 255.841  Millions$ 103.393  Millions
Forte Biosciences Inc   2.46 $ 58.223  Millions$ 23.647  Millions
Transcode Therapeutics Inc   2.42 $ 12.835  Millions$ 5.293  Millions
Cingulate Inc   2.42 $ 25.893  Millions$ 10.715  Millions
Madrigal Pharmaceuticals Inc   2.41 $ 812.771  Millions$ 336.562  Millions
Inmed Pharmaceuticals Inc  2.39 $ 5.242  Millions$ 2.195  Millions
Insmed Inc  2.38 $ 1,223.514  Millions$ 514.692  Millions
Uniqure N v   2.36 $ 139.994  Millions$ 59.197  Millions
Cue Biopharma Inc   2.36 $ 17.441  Millions$ 7.391  Millions
Schrodinger Inc   2.35 $ 398.959  Millions$ 169.542  Millions
Regeneron Pharmaceuticals Inc   2.33 $ 8,753.700  Millions$ 3,751.500  Millions
Greenwich Lifesciences Inc   2.30 $ 10.505  Millions$ 4.561  Millions

Date modified: 2026-09-12T06:10:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.